Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Crispr Therapeutics stock

Learn how to easily invest in Crispr Therapeutics stock.

Crispr Therapeutics is a biotechnology business based in the US. Crispr Therapeutics shares (CRSP) are listed on the NASDAQ and all prices are listed in US Dollars. Crispr Therapeutics employs 473 staff and has a trailing 12-month revenue of around $14.1 million.

How to buy Crispr Therapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – CRSP. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Promoted for easy user experience

Robinhood


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance

Promoted

tastyworks


  • $0 commissions on stocks and ETFs
  • $0 closing commissions on stock and ETF options
  • Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.

Crispr Therapeutics stock price (NASDAQ: CRSP)

Use our graph to track the performance of CRSP stocks over time.

Crispr Therapeutics shares at a glance

Information last updated 2023-01-25.
Latest market close$50.47
52-week range$38.94 - $86.95
50-day moving average $50.22
200-day moving average $60.41
Wall St. target price$95.30
PE ratio 13.234
Dividend yield $0 (0%)
Earnings per share (TTM) $3.76

Buy Crispr Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Crispr Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Crispr Therapeutics price performance over time

Historical closes compared with the close of $50.47 from 2023-01-26

1 week (2023-01-20) 1.73%
1 month (2022-12-27) 23.07%
3 months (2022-10-27) -3.61%
6 months (2022-07-27) -36.06%
1 year (2022-01-27) -14.11%
2 years (2021-01-27) -69.22%
3 years (2020-01-27) 53.59
5 years (2018-01-26) 27.93%

Is Crispr Therapeutics stock undervalued or overvalued?

Valuing Crispr Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Crispr Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Crispr Therapeutics's P/E ratio

Crispr Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Crispr Therapeutics shares trade at around 13x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Crispr Therapeutics financials

Revenue TTM $14.1 million
Gross profit TTM $476.3 million
Return on assets TTM -16.6%
Return on equity TTM -30.48%
Profit margin 0%
Book value $24.97
Market capitalisation $3.9 billion

TTM: trailing 12 months

Crispr Therapeutics share dividends

We're not expecting Crispr Therapeutics to pay a dividend over the next 12 months.

Have Crispr Therapeutics's shares ever split?

Crispr Therapeutics's shares were split on a 333333:100 basis on 18 July 2016. So if you had owned 100 shares the day before before the split, the next day you'd have owned 333333 shares. This wouldn't directly have changed the overall worth of your Crispr Therapeutics shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Crispr Therapeutics shares which in turn could have impacted Crispr Therapeutics's share price.

Crispr Therapeutics share price volatility

Over the last 12 months, Crispr Therapeutics's shares have ranged in value from as little as $38.94 up to $86.95. A popular way to gauge a stock's volatility is its "beta".

CRSP.US volatility(beta: 1.6)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crispr Therapeutics's is 1.5982. This would suggest that Crispr Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Crispr Therapeutics overview

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc.

Frequently asked questions

What percentage of Crispr Therapeutics is owned by insiders or institutions?
Currently 1.467% of Crispr Therapeutics shares are held by insiders and 69.002% by institutions.
How many people work for Crispr Therapeutics?
Latest data suggests 473 work at Crispr Therapeutics.
When does the fiscal year end for Crispr Therapeutics?
Crispr Therapeutics's fiscal year ends in December.
Where is Crispr Therapeutics based?
Crispr Therapeutics's address is: Baarerstrasse 14, Zug, Switzerland, 6300
What is Crispr Therapeutics's ISIN number?
Crispr Therapeutics's international securities identification number is: CH0334081137
What is Crispr Therapeutics's CUSIP number?
Crispr Therapeutics's Committee on Uniform Securities Identification Procedures number is: H17182108

More guides on Finder

Ask an Expert

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site